AI Article Synopsis
- Glioblastoma (GBM) is a deadly brain tumor with a very low five-year survival rate, highlighting the need for better treatment options and prognostic markers.
- The translocator protein 18kDa (TSPO) is linked to neuroinflammation and plays a role in GBM progression, with a specific genetic variant (rs6971) showing potential significance in disease outcomes.
- A study found that the rs6971 polymorphism is associated with shorter survival times in male GBM patients, indicating its potential as a sex-specific biomarker for poor prognosis in this disease.
Article Abstract
Glioblastoma (GBM) is the most common primary brain tumor in adults, with few available therapies and a five-year survival rate of 7.2%. Hence, strategies for improving GBM prognosis are urgently needed. The translocator protein 18kDa ) plays crucial roles in essential mitochondria-based physiological processes and is a validated biomarker of neuroinflammation, which is implicated in GBM progression. The gene has a germline single nucleotide polymorphism, rs6971, which is the most common SNP in the Caucasian population. High gene expression is associated with reduced survival in GBM patients; however, the relation between the most frequent genetic variant and GBM pathogenesis is not known. The present study retrospectively analyzed the correlation of the polymorphic variant rs6971 with overall and progression-free survival in GBM patients using three independent cohorts. rs6971 polymorphism was significantly associated with shorter overall survival and progression-free survival in male GBM patients but not in females in one large cohort of 441 patients. We observed similar trends in two other independent cohorts. These observations suggest that the rs6971 polymorphism could be a significant predictor of poor prognosis in GBM, with a potential for use as a prognosis biomarker in GBM patients. These results reveal for the first time a biological sex-specific relation between rs6971 polymorphism and GBM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471762 | PMC |
| http://dx.doi.org/10.3390/cancers13184525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.
Clin Transl Oncol
December 2024
Lillian S Wells Department of Neurosurgery at the University of Florida: University of Florida Lillian S Wells Department of Neurosurgery, Gainesville, FL, USA.
Glioblastoma (GBM) is one of the most common primary malignant brain tumors. Annually, there are about six instances recorded per 100,000 inhabitants. Treatment for GB has not advanced all that much.
View Article and Find Full Text PDFExploring the role of Disulfidptosis in glioma progression: insights into tumor heterogeneity and therapeutic potential through single-cell RNA sequencing.
Discov Oncol
December 2024
Department of Neurosurgery, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Wuhou District, Chengdu, China.
Background: Gliomas, particularly glioblastoma (GBM), are the most common and aggressive primary brain tumors in adults, characterized by high malignancy and frequent recurrence. Despite standard treatments, including surgery, radiotherapy, and chemotherapy, the prognosis for GBM remains poor, with a median survival of less than 15 months and a five-year survival rate below 10%. Tumor heterogeneity and resistance to treatment create significant challenges in controlling glioma progression.
View Article and Find Full Text PDFRelationship between glioblastoma location and O-methylguanine-DNA methyltransferase promoter methylation percentage.
Brain Commun
December 2024
Department of Neuroscience, University of Padova, 35121 Padova, Italy.
A large literature assessed the relationships between the O-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and glioblastoma location with inconsistent results. Studies assessing this association using the percentage of methylation are lacking. This cross-sectional study aimed at investigating relationships between glioblastoma topology and MGMT promoter methylation, both as categorical (presence/absence) and continuous (percentage) status.
View Article and Find Full Text PDFPhase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.
Neurooncol Adv
December 2024
Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Background: This study is a phase II clinical trial to evaluate the efficacy, safety, and tolerability of the blood-brain barrier (BBB) permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma (HGG) (NCT01967810).
Methods: Seventy-three patients were enrolled in 3 separate arms-recurrent glioblastoma (GBM) (Arm 1), bevacizumab refractory GBM (Arm 2), and grade 3 anaplastic gliomas (AGs) (Arm 3). The study was started in October 2013, and the data were locked on September 29, 2017.
Glutathione peroxidase 4 overexpression induces anomalous subdiffusion and impairs glioblastoma cell growth.
J Biol Eng
December 2024
Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA.
Glioblastoma tumors are the most common and aggressive adult central nervous system malignancy. Nearly all patients experience disease progression, which significantly contributes to disease mortality. Recently, it has been suggested that recurrent tumors may be characterized by a ferroptosis-prone phenotype with a significant decrease in glutathione peroxidase 4 (GPx4) expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!